The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Fayzrakhmanov R.R.

National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russia;
Institute of Advanced Training of Physicians of the National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russia

Petrachkov D.V.

Krasnov Research Institute of Eye Diseases, Moscow, Russia

Pavlovskiy O.A.

National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russia;
Institute of Advanced Training of Physicians of the National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russia

Martynov A.O.

National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russia

Saraeva S.N.

National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russia

Diabetic retinopathy and diabetic macular edema: etiopathogenesis and vitreoretinal surgery as one of the methods of treatment

Authors:

Fayzrakhmanov R.R., Petrachkov D.V., Pavlovskiy O.A., Martynov A.O., Saraeva S.N.

More about the authors

Journal: Russian Annals of Ophthalmology. 2026;142(2): 86‑91

DOI: 10.17116/oftalma202614202186

Read: 410 times

Contact the author
Table of contents

DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA: ETIOPATHOGENESIS AND VITREORETINAL SURGERY AS ONE OF THE METHODS OF TREATMENT
DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA: ETIOPATHOGENESIS AND VITREORETINAL SURGERY AS ONE OF THE METHODS OF TREATMENT

To cite this article:

Fayzrakhmanov RR, Petrachkov DV, Pavlovskiy OA, Martynov AO, Saraeva SN. Diabetic retinopathy and diabetic macular edema: etiopathogenesis and vitreoretinal surgery as one of the methods of treatment. Russian Annals of Ophthalmology. 2026;142(2):86‑91. (In Russ.)
https://doi.org/10.17116/oftalma202614202186

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Anatomical and functional outcomes of full-thickness macu­lar hole treatment using the opti­mized method of auto­logous reti­nal transplantation (preliminary report). Russian Annals of Ophthalmology. 2025;(4):80-86
Early vitrectomy in the treatment of diabetic reti­nopathy. Russian Annals of Ophthalmology. 2025;(5):87-93
Use of fari­cimab in neovascular age-related macu­lar dege­neration and diabetic macu­lar edema in Russia. Resu­lts of the FARWATER retrospective study. Russian Annals of Ophthalmology. 2025;(6):82-91
Analysis the frequency of using Afli­bercept (8 mg) in the treatment of neovascular age-related macu­lar dege­neration and diabetic macu­lar edema compared with other anti-VEGF agents. Russian Annals of Ophthalmology. 2025;(6):92-100
Auto­logous reti­nal transplantation in the surgery of large full-thickness macu­lar holes. Russian Annals of Ophthalmology. 2026;(1):124-130
Cost analysis of afli­bercept 8 mg versus other anti-VEGF agents. Russian Annals of Ophthalmology. 2026;(2):40-48
Endo­phthalmitis: pathogenesis, current methods of diagnosis and treatment. Russian Annals of Ophthalmology. 2026;(2):115-120
Acoustic analysis of changes in the lens layers after intravitreal dexa­methasone implant inje­ction. Russian Annals of Ophthalmology. 2026;(3):22-28
Clinical and economic impact of broader implementation of opti­cal cohe­rence tomo­graphy and anti-VEGF therapy for diabetic reti­nopathy and macu­lar edema in type 1 diabetes. Medi­cal Technologies. Asse­ssment and Choice. 2026;(1):122-133
Abstract:

Complications of diabetes mellitus such as diabetic retinopathy (DR) and diabetic macular edema (DME) remain major global health concerns. DME leads to swelling of the central retina and consequently to decreased visual acuity. The pathogenesis of these conditions is complex and multifactorial, and continues to be the subject of scientific research. Currently, intravitreal injections of angiogenesis inhibitors are considered the main method of DME treatment. However, their prolonged use may lead to patients developing treatment resistance. With the advancement of vitreoretinal surgery, its therapeutic potential in DME management is being actively explored. In patients with diabetes mellitus and DME, resistance may develop to antivasoproliferative therapy, laser treatment, or dexamethasone implant therapy. Introduction of vitreoretinal surgical techniques into DME management allows for improvement of anatomical and functional outcomes within a short time in patients with this pathology.

Keywords:

vitrectomy
diabetic macular edema
BSS
membrane peeling
diabetic retinopathy

Authors:

Fayzrakhmanov R.R.

National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russia;
Institute of Advanced Training of Physicians of the National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russia

Petrachkov D.V.

Krasnov Research Institute of Eye Diseases, Moscow, Russia

Pavlovskiy O.A.

National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russia;
Institute of Advanced Training of Physicians of the National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russia

Martynov A.O.

National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russia

Saraeva S.N.

National Medical and Surgical Center named after N.I. Pirogov, Moscow, Russia

Received:

10.09.2025

Accepted:

13.11.2025

Close metadata

References:

  1. Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology. 2009;116(3):497-503.  https://doi.org/10.1016/j.ophtha.2008.10.016
  2. Dedov II, Shestakova MV, Vikulova OK, et al. Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021. Diabetes mellitus. 2021;24(3):204-21. (In Russ.). https://doi.org/10.14341/DM12759
  3. International Diabetes Federation (2021) IDF Diabetes Atlas 10th Edition. https://diabetesatlas.org/atlas/tenth-edition
  4. Burton MJ, Ramke J, Marques AP, et al. The Lancet Global Health Commission on Global Eye Health: vision beyond 2020. Lancet Glob Health. 2021 Apr;9(4):e489-e551. https://doi.org/10.1016/S2214-109X(20)30488-5
  5. Daruich A, Matet A, Moulin A, Kowalczuk L, Nicolas M, Sellam A, Rothschild PR, Omri S, Gélizé E, Jonet L, Delaunay K, De Kozak Y, Berdugo M, Zhao M, Crisanti P, Behar-Cohen F. Mechanisms of macular edema: Beyond the surface. Prog Retin Eye Res. 2018 Mar;63:20-68.  https://doi.org/10.1016/j.preteyeres.2017.10.006
  6. Burke SJ, Karlstad MD, Eder AE, Regal KM, Lu D, Burk DH, et al. Pancreatic beta-Cell production of CXCR3 ligands precedes diabetes onset. Biofactors. 2016;42(6):703-15.  https://doi.org/10.1002/biof.1304
  7. Filippov VM, Petrachkov DV, Budzinskaya MV, Sidamonidze AL. Modern concepts of pathogenesis of diabetic retinopathy. Russian Annals of Ophthalmology. 2021;137(5-2):306-313. (In Russ.). https://doi.org/10.17116/oftalma2021137052306
  8. Xu H, Czerwinski P, Hortmann M, Sohn HY, Forstermann U, Li H. Protein kinase C alpha promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor. Cardiovasc Res. 2008;78:349-355.  https://doi.org/10.1093/cvr/cvm085
  9. Campochiaro PA, Akhlaq A. Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases. Prog Retin Eye Res. 2021;83:100921. https://doi.org/10.1016/j.preteyeres.2020.100921
  10. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Inv Ophthalmol Vis Sci. 2001;42:2408-2413.
  11. Mishra S, Mishra BB. Study of Lipid Peroxidation, Nitric Oxide End Product, and Trace Element Status in Type 2 Diabetes Mellitus with and without Complications. Int J Appl Basic Med Res. 2017;7(2):88-93.  https://doi.org/10.4103/2229-516X.205813
  12. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653-64. pmid: 12941734. https://doi.org/10.2337/diacare.26.9.2653
  13. Petrachkov DV, Korobov EN, Arzhukhanov DD. Role of Vitrectomy in the Treatment of Diabetic Retinopathy. Ophthalmology in Russia. 2021;18(3S): 718-726. (In Russ.). https://doi.org/10.18008/1816-5095-2021-3S-718-726
  14. Babaeva DB, Shishkin MM. Biomechanical impact of the vitreous in the pathophysiology of diabetic vitreopapillary traction syndrome. Sovremennye tekhnologii v oftal’mologii. 2020;1(32):103-106. (In Russ.). https://doi.org/10.25276/2312-4911-2020-2-103-106
  15. Duh E, Aiello LP. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes. 1999;48(10):1899-906. PMID: 10512352  https://doi.org/10.2337/diabetes.48.10.1899
  16. Saker S, Stewart EA, Browning AC, Allen CL, Amoaku WM. The effect of hyperglycaemia on permeability and the expression of junctional complex molecules in human retinal and choroidal endothelial cells. Experimental Eye Research. 2014; 121: 161-167.  https://doi.org/10.1016/j.exer.2014.02.016
  17. Deissler HL, Deissler H, Lang GE. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells. Br J Ophthalmol. 2011;95(8):1151-1156. https://doi.org/10.1136/bjo.2010.192229
  18. Gonzalez-Salinas R, Garcia-Gutierrez MC, Garcia-Aguirre G, Morales-Canton V, Velez-Montoya R, Soberon-Ventura VR, et al. Evaluation of VEGF gene polymorphisms and proliferative diabetic retinopathy in Mexican population. Int J Ophthalmol. 2017;10(1):135-139.  https://doi.org/10.18240/ijo.2017.01.22pmid:28149790
  19. Eleiwa KT, Bayoumy A, Elhusseiny MA, Gamil K, Sharawy A. Longitudinal analysis of subfoveal choroidal thickness after panretinal laser photocoagulation in diabetic retinopathy using swept-source optical coherence tomography. Rom J Ophthalmol. 2020;64:285-291.  https://doi.org/10.22336/rjo.2020.46
  20. Sadiq MA, Halim MS, Hassan M, Onghanseng N, Karaca I, Agarwal A, Afridi R, Sepah YJ, Do DV, Nguyen QD. Pharmacological agents in development for diabetic macular edema. Int J Retina Vitreous. 2020 Jul 8;6:29.  https://doi.org/10.1186/s40942-020-00234-z
  21. Liberski S, Wichrowska M, Kocięcki J. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. Int J Mol Sci. 2022 Aug 20;23(16):9424. https://doi.org/10.3390/ijms23169424
  22. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-25.  https://doi.org/10.1016/j.ophtha.2011.01.031
  23. Amoaku WM, Saker S, Stewart EA. A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye. 2015;29(9): 1115-1130. https://doi.org/10.1038/eye.2015.110
  24. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-1146e3. https://doi.org/10.1016/j.ophtha.2010.03.032
  25. Fayzrakhmanov RR, Shishkin MM, Shatalova EO, Suhanova AV. Early switch from anti-VEGF Therapy to dexamethasone implant in diabetic macular edema. Fyodorov Journal of Ophthalmic Surgery. 2020;4:86-92. (In Russ.). https://doi.org/10.25276/0235-4160-2020-4-86-92
  26. Kang YK, Park HS, Park DH, Shin JP. Incidence and treatment outcomes of secondary epiretinal membrane following intravitreal injection for diabetic macular edema. Sci Rep. 2020;10:528.  https://doi.org/10.1038/s41598-020-57509-6
  27. Haller JA, Qin H, Apte RS, Beck RR, Bressler NM, Browning DJ, Danis RP, Glassman AR, Googe JM, Kollman C, Lauer AK, Peters MA, Stockman ME: Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010;117:1087-1093.e1083.
  28. Petrachkov DV, Budzinskaya MV, Matyushchenko AG, Sidamonidze AL, Filippov VM. Viscodissection with staining of epiretinal membranes in surgery of proliferative diabetic retinopathy. Russian Annals of Ophthalmology. 2021;137(4):18-23. (In Russ., In Engl.). https://doi.org/10.17116/oftalma202113704118
  29. Zotov VV, Pashtaev NP, Pozdeeva NA «Mono-instrumental» 27 G-vitrectomy in the treatment of proliferative diabetic retinopathy. Modern technologies in ophthalmology. 2018; 21(1):159-161. (In Russ.).
  30. Petrachkov DV, Filippov VM, Alkharki L. Comparative analysis of the diabetic retinopathy surgical treatment results in patients with various types of diabetes mellitus. Oftal’mologiya. Vostochnaya Evropa. 2022;12(4):435-447. (In Russ.). https://doi.org/10.34883/PI.2022.12.4.013
  31. Shkvorchenko DO, Kakunina SA, Belousova EV, Rusanovskaya AV. Technique of bimanual 27-29G vitrectomy in the treatment of proliferative diabetic retinopathy. Modern technologies for the treatment of vitreoretinal pathology — 2012: Collection of abstracts. Federal State Budgetary Institution “MNTK “Microsurgery of the Eye”. — Moscow, 2012. — 209 p. (In Russ.).
  32. Fayzrakhmanov RR, Pavlovskiy OA, Larina EA. The method of closure of macular holes with a partial peeling of the internal limiting membrane: comparative analysis. Russian biomedical journal Medline.ru. 2019; 20: 187-200. (In Russ.).
  33. Fayzrakhmanov RR, Pavlovskiy OA, Larina EA. Modern methods of operative intervention of patients with macular hole. Bulletin of the National Medical and Surgical Center. N.I. Pirogov. 2019; 14 (2): 98-104. (In Russ.). https://doi.org/10.25881/BPNMSC.2018.64.37.021
  34. Wong Y, Steel DHW, Habib MS, Stubbing-Moore A, Bajwa D, Avery PJ. Vitreoretinal interface abnormalities in patients treated with ranibizumab for diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol. 2017;255(4):733-742.  https://doi.org/10.1007/s00417-016-3562-0
  35. Akbar Khan I, Mohamed MD, Mann SS, Hysi PG, Laidlaw DA. Prevalence of vitreomacular interface abnormalities on spectral domain optical coherence tomography of patients undergoing macular photocoagulation for Centre involving diabetic macular oedema. Br J Ophthalmol. 2015;99(8):1078-1081. https://doi.org/10.1136/bjophthalmol-2014-305966
  36. Hagenau F, Vogt D, Ziada J, Guenther SR, Haritoglou C, Wolf A, Priglinger SG, Schumann RG. Vitrectomy for diabetic macular edema: optical coherence tomography criteria and pathology of the Vitreomacular Interface. Am J Ophthalmol. 2019;200:34-46.  https://doi.org/10.1016/j.ajo.2018.12.004
  37. Iglicki M, Lavaque A, Ozimek M, Negri HP, Okada M, Chhablani J, Busch C, Loewenstein A, Zur D. Biomarkers and predictors for functional and anatomic outcomes for small gauge pars plana vitrectomy and peeling of the internal limiting membrane in naïve diabetic macular edema: the VITAL study. PLoS One. 2018;13(7):e0200365. https://doi.org/10.1371/journal.pone.0200365
  38. Stefánsson E. Ocular oxygenation and the treatment of diabetic retinopathy. Surv Ophthalmol. 2006;51:364-380.  https://doi.org/10.1016/j.survophthal.2006.04.005
  39. Kadonosono K, Itoh N, Ohno S. Perifoveal microcirculation before and after vitrectomy for diabetic cystoid macular edema. Am J Ophthalmol. 2000; 130:740-744.  https://doi.org/10.1016/S0002-9394(00)00575-4
  40. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: Vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes. 1998;47:1953-1959. https://doi.org/10.2337/diabetes.47.12.1953
  41. Lee SS, Ghosn C, Yu Z, Zacharias LC, Kao H, Lanni C, Abdelfattah N, Kuppermann B, Csaky KG, D’Argenio DZ, Burke JA, Hughes PM, Robinson MR. Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2135-8.  https://doi.org/10.1167/iovs.09-3582
  42. Sdobnikova SV, Sdobnikova LE. Vitrectomy is the method of choice in the treatment of proliferative diabetic retinopathy combined with diffuse macular edema. Point of view. East-West. 2018; 2: 35-38. (In Russ.).
  43. Abdel Hadi AM. Evaluation of Vitrectomy with Planned Foveal Detachment as Surgical Treatment for Refractory Diabetic Macular Edema with or without Vitreomacular Interface Abnormality. J Ophthalmol. 2018 May 7;2018: 9246384. https://doi.org/10.1155/2018/9246384
  44. Morizane Y, Kimura S, Hosokawa M, Shiode Y, Hirano M, Doi S, Hosogi M, Fujiwara A, Inoue Y, Shiraga F. Planned foveal detachment technique for the resolution of diffuse diabetic macular edema. Jpn J Ophthalmol. 2015 Sep;59(5):279-287.  https://doi.org/10.1007/s10384-015-0390-4
  45. Asahina Y, Tachi N, Asahina Y, Yoshimura K, Ueta Y, Hashimoto Y. Six-month postoperative outcomes of intraoperative OCT-guided surgical cystotomy for refractory cystoid macular edema in diabetic eyes. Clin Ophthalmol. 2017 Nov 23;11:2099-2105. https://doi.org/10.2147/OPTH.S150385
  46. Yanyali A, Bozkurt KT, Macin A, Horozoglu F, Nohutcu AF. Quantitative assessment of photoreceptor layer in eyes with resolved edema after pars plana vitrectomy with internal limiting membrane removal for diabetic macular edema. Ophthalmologica. 2011;226(2):57-63.  https://doi.org/10.1159/000327597
  47. Chhablani JK, Kim JS, Cheng L, Kozak I, Freeman W. External limiting membrane as a predictor of visual improvement in diabetic macular edema after pars plana vitrectomy. Graefes Arch Clin Exp Ophthalmol. 2012;250(10): 1415-1420. https://doi.org/10.1007/s00417-012-1968-x
  48. Bikbov MM, Fayzrakhmanov RR, Kalanov MR. Effect of peeling of the internal border membrane on the morphofunctional parameters of the retina in proliferative diabetic retinopathy (preliminary report). Vestnik oftal’mologii. 2018;134(1):63-69. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.